Glaxo–SmithKline merger: sooner than later? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glaxo–SmithKline merger: sooner than later?

Aug 14, 2000

Glaxo India and SmithKline Pharma, it seems, are proceeding apace with their merger in India much sooner than expected. Though the details are not known, one indication of this came at the analysts meet of Glaxo India when the Managing Director Mr. Khusrokhan refused to talk about the merger saying that it could impact the share prices of the two companies. We have tried to hypothecate about the merger ratio between the two companies assuming of course that Burroughs Wellcome and SmithKline Consumer are kept out of the merger temporarily. While the Glaxo management has clearly indicated that the amalgamation with Burroughs has been put on to the back burner, the decision about SmithKline Consumer is likely to be taken at the global headquarters since Glaxo has already sold its foods portfolio (comprising ‘Farex’ and ‘Glucon D’) worldwide. Even in India the food division was sold to Heinz. SmithKline abroad is more of a pharma company with the major operations of ‘Horlicks’ in the UK apart from a sizeable presence in India.

Both the companies came out of a trough in the second quarter and reported outstanding results despite an adverse industry environment. While Glaxo reported a 27% jump in the topline in the second quarter, SmithKline also reported a 50% jump at the pre–tax level. And this despite a fall in the topline!

If one were to make a forecast the second half keeping in mind the forecast made by Mr. Khusrokhan (he spoke a 15% growth, for the full year at best), Glaxo would end up reporting a net in the range of Rs 800m, SmithKline would in all probability end up with a net in the range of of Rs 200 m.

Assuming a 1:2.5 ratio (i.e. 2.5 shares of SmithKline for every 1 share of Glaxo), the merged entity would end up with an equity of around Rs 716 m (post merger) and a per share earnings of Rs.13.89.

At a price earnings of around 40, the merged company could quote at levels of Rs 560–570. While Glaxo currently quotes at a price of Rs 470, SmithKline Pharma is quoting at the price of 158. Thus if a merger were to materialise the market prices are actually indicative of a 1:3 ratio (i.e. one share of Glaxo for every three of SmithKline Pharma). This could be taking into account the cash and the value of the properties that Glaxo holds. (Glaxo holds cash and marketable investments of almost Rs 600 m besides valuable real estate at Mumbai, which it has leased out.)


Equitymaster requests your view! Post a comment on "Glaxo–SmithKline merger: sooner than later?". Click here!

  

More Views on News

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 29, 2020 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - UNICHEM LAB COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS